

## **GenoMed Completes First Version of Healthchip(r) for Cancer Prediction**

FOR IMMEDIATE RELEASE

Contact:  
David Moskowitz MD  
tel. 314-983-9933  
GenoMed, Inc.

ST. LOUIS, April 20, 2005 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company, said today that it has constructed a Healthchip® which may serve as an early warning system for the top six common cancers in whites: breast, colon, lung, ovarian, pancreatic, and prostate.

GenoMed's Healthchip® is made up of many single nucleotide polymorphisms (SNPs). In internal testing, the Healthchip® correctly identified the type of cancer in 85% of cases. None of the normals were misdiagnosed. More testing is required to confirm these results.

The well known breast cancer genes, BRCA1 and BRCA2, account for only 5% of breast cancers in white women. GenoMed's SNPs may pick up the remaining 95% of sporadic breast cancer cases in white women, i.e. in women without a strong family history of breast cancer.

Said Dr. David Moskowitz, GenoMed's chairman and chief executive officer, "It's important for any screening test to have as few false positives as possible. GenoMed's Healthchip® currently has none."

The test for mutations in the BRCA1 and BRCA2 genes costs about \$1,200, has been available for about a decade, and has been reimbursed by a handful of insurance plans for the past few years. GenoMed's test is currently available for research purposes only, and is not yet reimbursable by any health plan. Please contact Dr. Moskowitz at [dwmoskowitz@genomed.com](mailto:dwmoskowitz@genomed.com) to inquire about GenoMed's testing program.

### About GenoMed

GenoMed is leading the clinical revolution which knowledge of disease genes has already begun. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company also conducts basic research to find genes that cause different diseases and clinical research to test protocols that look promising for improving patient outcomes. The company plans next to collect patient samples from additional cancer types, and additional ethnic groups so as to increase the scope and usefulness of its Healthchip®.

### Safe Harbor Statement

This press release contains forward-looking statements pertaining to GenoMed, Inc.'s (The Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties including, but not limited to: (a) whether subsequent research confirms that the SNPs we've found are truly linked to common cancers; and (b) our research and development being subject to economic, regulatory, governmental and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments unanticipated events or circumstances after the date of such statement.